173 related articles for article (PubMed ID: 10987276)
21. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.
Hatfield MJ; Tsurkan L; Garrett M; Shaver TM; Hyatt JL; Edwards CC; Hicks LD; Potter PM
Biochem Pharmacol; 2011 Jan; 81(1):24-31. PubMed ID: 20833148
[TBL] [Abstract][Full Text] [Related]
22. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.
Morton CL; Wierdl M; Oliver L; Ma MK; Danks MK; Stewart CF; Eiseman JL; Potter PM
Cancer Res; 2000 Aug; 60(15):4206-10. PubMed ID: 10945631
[TBL] [Abstract][Full Text] [Related]
23. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
24. Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.
Wierdl M; Morton CL; Nguyen NK; Redinbo MR; Potter PM
Biochemistry; 2004 Feb; 43(7):1874-82. PubMed ID: 14967028
[TBL] [Abstract][Full Text] [Related]
25. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Kojima A; Hackett NR; Ohwada A; Crystal RG
J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
[TBL] [Abstract][Full Text] [Related]
26. Structural insights into CPT-11 activation by mammalian carboxylesterases.
Bencharit S; Morton CL; Howard-Williams EL; Danks MK; Potter PM; Redinbo MR
Nat Struct Biol; 2002 May; 9(5):337-42. PubMed ID: 11967565
[TBL] [Abstract][Full Text] [Related]
27. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Rivory LP; Bowles MR; Robert J; Pond SM
Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
[TBL] [Abstract][Full Text] [Related]
28. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
29. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
30. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
31. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs.
Senter PD; Marquardt H; Thomas BA; Hammock BD; Frank IS; Svensson HP
Cancer Res; 1996 Apr; 56(7):1471-4. PubMed ID: 8603386
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
33. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
Hicks LD; Hyatt JL; Stoddard S; Tsurkan L; Edwards CC; Wadkins RM; Potter PM
J Med Chem; 2009 Jun; 52(12):3742-52. PubMed ID: 19534556
[TBL] [Abstract][Full Text] [Related]
34. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Kehrer DF; Yamamoto W; Verweij J; de Jonge MJ; de Bruijn P; Sparreboom A
Clin Cancer Res; 2000 Sep; 6(9):3451-8. PubMed ID: 10999728
[TBL] [Abstract][Full Text] [Related]
35. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
[TBL] [Abstract][Full Text] [Related]
36. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
[TBL] [Abstract][Full Text] [Related]
37. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
Kaneda N; Nagata H; Furuta T; Yokokura T
Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.
Charasson V; Bellott R; Meynard D; Longy M; Gorry P; Robert J
Clin Pharmacol Ther; 2004 Dec; 76(6):528-35. PubMed ID: 15592324
[TBL] [Abstract][Full Text] [Related]
39. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
[TBL] [Abstract][Full Text] [Related]
40. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Guichard S; Terret C; Hennebelle I; Lochon I; Chevreau P; Frétigny E; Selves J; Chatelut E; Bugat R; Canal P
Br J Cancer; 1999 May; 80(3-4):364-70. PubMed ID: 10408839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]